Gilead Sciences Announces Third Quarter 2023 Financial Results
Retrieved on:
Tuesday, November 7, 2023
Biotechnology, Pharmaceutical, AIDS, Oncology, General Health, Health, Infectious Diseases, Hospitals, BIRCH, Food, Pembrolizumab, B-cell lymphoma, Impact of the COVID-19 pandemic on hospitals, EPS, COVID-19, Tax rate, ETR, CAPELLA, Cohort study, Infection, Acute lymphoblastic leukemia, American Association for the Study of Liver Diseases, SARS-CoV-2, Earnings per share, HIV, GAAP, HCV, Safety, Patient, Food and Drug Administration, European Commission, Conference, Obeldesivir, Research, Growth, European, Lung cancer, Total, HDV, PD-L1, Research and development, Incidence, Hepatology, Axicabtagene ciloleucel, Omicron, Liver, Lung, Risk, Science, FTC, Table, Liver disease, HBV, Pharmaceutical industry, Video game, Fine chemical, Security (finance), Virology, Sacituzumab govitecan, Remdesivir
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
Key Points:
- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
- During the third quarter of 2023, Gilead generated $1.8 billion in operating cash flow.
- During the third quarter of 2023, Gilead repaid $2.3 billion of debt, paid dividends of $953 million and repurchased $300 million of common stock.
- Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.